{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:19:42Z","timestamp":1795173582647,"version":"4.10.3"},"reference-count":32,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)\u2013targeting chimeric antigen receptor T-cell (CAR-T) approved for the treatment of relapsed and refractory multiple myeloma (RRMM). Currently, the incidence of cardiac events associated with ide-cel remains unclear. This was a retrospective single-center observational study of patients treated with ide-cel for RRMM. We included all consecutive patients who received standard-of-care ide-cel treatment at least 1-month follow-up. Baseline clinical risk factors, safety profile, and responses were examined based on the development of a cardiac event. A total of 78 patients were treated with ide-cel, and 11 patients (14.1%) developed cardiac events: heart failure (5.1%), atrial fibrillation (10.3%), nonsustained ventricular tachycardia (3.8%), and cardiovascular death (1.3%). Only 11 of the 78 patients had repeat echocardiogram. Baseline risk factors associated with the development of cardiac events included being female sex and having poor performance status, \u03bb light-chain disease, and advanced Revised International Staging System stage. Baseline cardiac characteristics were not associated with cardiac events. During index hospitalization after CAR-T, higher-grade (\u2265grade 2) cytokine release syndrome (CRS) and immune cell\u2013associated neurologic syndrome were associated with cardiac events. In multivariable analyses, the hazard ratio for the association of the presence of cardiac events with overall survival (OS) was 2.66 and progression-free survival (PFS) was 1.98. Ide-cel CAR-T for RRMM was associated with similar cardiac events as other types of CAR-T. Worse baseline performance status and higher-grade CRS and neurotoxicity were associated with cardiac events after BCMA-directed CAR-T-cell therapy. Our results suggest that the presence of cardiac events may confer worse PFS or OS; although because of the small sample size, the power to detect an association was limited.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023009766","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T16:33:28Z","timestamp":1686587608000},"page":"4247-4257","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-0404","authenticated-orcid":false,"given":"Dae Hyun","family":"Lee","sequence":"first","affiliation":[{"name":"1Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, FL"},{"name":"2Department of Cardio-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kumar","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-6419","authenticated-orcid":false,"given":"Turab","family":"Mohammed","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"},{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Peres","sequence":"additional","affiliation":[{"name":"6Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-3670","authenticated-orcid":false,"given":"Christina","family":"Bachmeier","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Blue","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brayer","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-1237","authenticated-orcid":false,"given":"Sanjay","family":"Chandrasekhar","sequence":"additional","affiliation":[{"name":"1Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, FL"},{"name":"2Department of Cardio-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Grajales Cruz","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe","family":"De Avila","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4636","authenticated-orcid":false,"given":"Hany","family":"Elmariah","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Faramand","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara","family":"Freeman","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael","family":"Jain","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-1700","authenticated-orcid":false,"given":"Sushmita","family":"Khadka","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Khimani","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-4381","authenticated-orcid":false,"given":"Hien","family":"Liu","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-2512","authenticated-orcid":false,"given":"Laura B.","family":"Oswald","sequence":"additional","affiliation":[{"name":"7Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar A.","family":"Castaneda Puglianini","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Smith","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme H.","family":"Oliveira","sequence":"additional","affiliation":[{"name":"1Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, FL"},{"name":"2Department of Cardio-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alomar","sequence":"additional","affiliation":[{"name":"1Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, FL"},{"name":"2Department of Cardio-Oncology, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"4Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"26","key":"2023082114241339000_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2023082114241339000_bib2","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023082114241339000_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023082114241339000_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023082114241339000_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2023082114241339000_bib6","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"2023082114241339000_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"12","key":"2023082114241339000_bib8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2023082114241339000_bib9","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2023082114241339000_bib10","doi-asserted-by":"crossref","first-page":"691064","DOI":"10.3389\/fonc.2021.691064","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: a single-centre retrospective study","volume":"11","author":"Qi","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"2023082114241339000_bib11","first-page":"18","article-title":"Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study","volume":"9","author":"Lee","year":"2023","journal-title":"Cardiooncology"},{"issue":"17","key":"2023082114241339000_bib12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"issue":"8","key":"2023082114241339000_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023082114241339000_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11936-018-0618-y","article-title":"Cardiovascular complications of multiple myeloma treatment: evaluation, management, and prevention","volume":"20","author":"Lee","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"4","key":"2023082114241339000_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023082114241339000_bib16","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0","year":"2017"},{"issue":"8","key":"2023082114241339000_bib17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"41","key":"2023082114241339000_bib18","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2023082114241339000_bib19","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J\u00a0Biomed Inform"},{"issue":"11","key":"2023082114241339000_bib20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2023082114241339000_bib21","author":"R Core Team","year":"2021"},{"issue":"22","key":"2023082114241339000_bib22","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023082114241339000_bib23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2023082114241339000_bib24","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J\u00a0Card Fail"},{"issue":"22","key":"2023082114241339000_bib25","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"2023082114241339000_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2023082114241339000_bib27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular events in patients treated with chimeric antigen receptor t-cell therapy for aggressive B-cell lymphoma","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"2023082114241339000_bib28","doi-asserted-by":"crossref","first-page":"e004947","DOI":"10.1161\/CIRCIMAGING.116.004947","article-title":"Multimodality cardiac imaging for the assessment of left atrial function and the association with atrial arrhythmias","volume":"9","author":"Olsen","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023082114241339000_bib29","doi-asserted-by":"crossref","first-page":"101634","DOI":"10.1016\/j.jaccas.2022.09.004","article-title":"Case of myocarditis after chimeric antigen receptor T cells with intracardiac lymphoma","volume":"8","author":"Lee","year":"2023","journal-title":"JACC Case Rep"},{"issue":"2","key":"2023082114241339000_bib30","doi-asserted-by":"crossref","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"2023082114241339000_bib31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jjco\/hyy202","article-title":"Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma","volume":"49","author":"Kobayashi","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"2023082114241339000_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas","year":"2020","journal-title":"Amyloid"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4247\/2072782\/blooda_adv-2023-009766-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4247\/2072782\/blooda_adv-2023-009766-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T14:24:44Z","timestamp":1692627884000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4247\/496261\/Cardiac-events-after-standard-of-care-idecabtagene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023009766","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]}}}